R21/Matrix-M Malaria Vaccine Phase 3 Results & Challenges in Sub-Saharan Africa
The R21/Matrix-M malaria vaccine shows promising Phase 3 results, yet faces significant challenges in deployment across Sub-Saharan Africa.
Quick Answer
The R21/Matrix-M malaria vaccine shows promising Phase 3 results, yet faces significant challenges in deployment across Sub-Saharan Africa.
Key Questions
- What is the efficacy of R21/Matrix-M malaria vaccine in Phase 3 trials?
- When did WHO recommend the R21/Matrix-M malaria vaccine?
- How does R21/Matrix-M compare to RTS,S/AS01 malaria vaccine?
- What age group is the R21/Matrix-M vaccine approved for?
- What is the dosing schedule for R21/Matrix-M vaccine?
The R21/Matrix-M malaria vaccine demonstrated 75% efficacy against clinical malaria in seasonal transmission areas during Phase 3 trials, leading to WHO recommendation in October 2023 as the second malaria vaccine for children after RTS,S/AS01. Results published in The Lancet showed the Oxford-developed vaccine could help close the supply gap for malaria prevention in Africa.
Contents10 sections
Key Takeaways
- Phase 3 efficacy: R21/Matrix-M achieved 75% efficacy (95% CI: 71-79) at seasonal sites and 68% (95% CI: 61-74) at perennial sites, substantially outperforming RTS,S/AS01's ~30-40% efficacy (The Lancet, 2024).
- WHO recommendation: The vaccine received WHO recommendation on October 2, 2023, following advice from SAGE and MPAG, making it the second malaria vaccine recommended for widespread use (WHO, 2023).
- Market access: Gavi and UNICEF secured an equitable pricing deal at $2.99 per dose, with over 40 million doses delivered to 24 African countries as of late 2025 (Gavi, 2025).
- Rollout progress: Nigeria introduced R21 in December 2024, targeting high-burden states Bayelsa and Kebbi as part of phased implementation (WHO AFRO, 2024).
- Clinical trial design: The double-blind Phase 3 trial (NCT04704830) enrolled 4,800 children aged 5-36 months across Burkina Faso, Mali, Kenya, and Tanzania.
What Is the R21/Matrix-M Vaccine?
R21/Matrix-M is a protein malaria vaccine from the University of Oxford and Serum Institute of India. It combines the R21 antigen with Novavax's Matrix-M adjuvant.
The Matrix-M adjuvant boosts immune response. Each dose contains 5 μg R21 antigen plus 50 μg Matrix-M. The vaccine targets the pre-erythrocytic stage of malaria infection, aiming to prevent the parasite from infecting liver cells.
What Did the Phase 3 Trial Show?
The Phase 3 trial was a double-blind study across five sites in Burkina Faso, Mali, Kenya, and Tanzania. NCT04704830 enrolled 4,800 children aged 5-36 months.
Children were assigned (2:1) to receive R21/Matrix-M or a rabies control vaccine. The study measured protection from 14 days after dose 3 through 12 months.
| Endpoint | Seasonal Sites | Perennial Sites |
|---|---|---|
| Time to first clinical malaria episode | 75% (95% CI: 71-79) | 68% (95% CI: 61-74) |
| Multiple clinical malaria episodes | 75% (95% CI: 71-78) | 67% (95% CI: 59-73) |
The vaccine was well tolerated. The most frequent adverse events were injection site pain (18.6%) and fever (46.7%). No treatment-related deaths occurred.
How Does R21/Matrix-M Compare to RTS,S/AS01?
RTS,S/AS01 (Mosquirix) was the first malaria vaccine to receive WHO recommendation in 2021. However, supply constraints have limited its rollout. R21/Matrix-M offers several advantages:
- Efficacy: R21/Matrix-M demonstrated 75% efficacy in seasonal areas versus approximately 30-40% for RTS,S/AS01 in similar transmission settings.
- Price: At $2.99 per dose, R21/Matrix-M is priced competitively to enable broad access.
- Supply: The Serum Institute of India has committed to producing 100 million doses annually.
- Dosing: Both vaccines require a 3-dose primary series plus booster, but R21/Matrix-M uses a 4-week interval versus RTS,S/AS01's monthly schedule.
Both vaccines are now part of Gavi's malaria vaccination programme, which aims to vaccinate 50 million children by 2030.
What Is the Regulatory Status in Africa?
WHO prequalification enables procurement through UN agencies and Gavi. After the October 2023 WHO recommendation, several African countries began using R21/Matrix-M:
Nigeria: Launched rollout in December 2024, starting with Bayelsa and Kebbi states. Nigeria accounts for approximately 27% of global malaria burden.
Ghana: Among early adopters, Ghana integrated R21 into routine immunization alongside existing malaria control measures.
Other markets: Regulatory pathways through the African Medicines Agency (AMA) and national regulators like SAHPRA are advancing harmonized review processes.
What Is the Market Outlook?
Demand for malaria vaccines far exceeds current supply. Gavi estimates that adding R21/Matrix-M will enable sufficient supply to protect all children in malaria-endemic areas. The November 2025 pricing agreement with UNICEF is expected to generate up to $90 million in savings, equivalent to more than 30 million additional doses.
Key market factors:
- Over 40 million doses delivered through Gavi programmes as of late 2025
- 24 African countries have integrated malaria vaccines into routine immunization
- Serum Institute of India capacity: 100 million doses annually
- Gavi target: 50 million children vaccinated by 2030
What Are the Implementation Challenges?
Despite strong efficacy data, several challenges remain for widespread R21/Matrix-M implementation:
Delivery infrastructure: The 4-week dosing interval requires strong cold chain and scheduling systems. Seasonal vaccination strategies may require coordination with malaria transmission patterns.
Duration of protection: A modest reduction in vaccine efficacy was observed over the first 12 months. The trial is ongoing to assess longer-term protection and optimal booster strategies.
Supply coordination: Balancing demand across countries with varying malaria burden and health system capacity requires careful planning through Gavi and WHO.
Frequently Asked Questions
What is the efficacy of R21/Matrix-M malaria vaccine in Phase 3 trials?
R21/Matrix-M demonstrated 75% efficacy (95% CI: 71-79) against clinical malaria at seasonal transmission sites and 68% efficacy (95% CI: 61-74) at standard sites with perennial transmission, according to Phase 3 results published in The Lancet.
When did WHO recommend the R21/Matrix-M malaria vaccine?
WHO recommended the R21/Matrix-M malaria vaccine on October 2, 2023, following advice from the Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory Group (MPAG).
How does R21/Matrix-M compare to RTS,S/AS01 malaria vaccine?
R21/Matrix-M showed significantly higher efficacy (75% seasonal, 68% perennial) compared to RTS,S/AS01, which demonstrated approximately 30-40% efficacy in similar settings. R21/Matrix-M is also priced lower at $2.99 per dose versus RTS,S/AS01's higher cost.
What age group is the R21/Matrix-M vaccine approved for?
The R21/Matrix-M vaccine is indicated for children aged 5-36 months in malaria-endemic regions. The Phase 3 trial enrolled 4,800 children across five sites in Burkina Faso, Mali, Kenya, and Tanzania.
What is the dosing schedule for R21/Matrix-M vaccine?
R21/Matrix-M is administered as three doses, 4 weeks apart, with a booster dose given 12 months after the third dose. Each dose contains 5 μg R21 antigen plus 50 μg Matrix-M adjuvant.
Primary Sources
- Datoo MS, Natama MH, Some A, et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet. 2024;403(10433): 533-546. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02511-4/fulltext
- World Health Organization. WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization. October 2, 2023. https://www.who.int/news/item/02-10-2023-who-recommends-r21-matrix-m-vaccine
- ClinicalTrials.gov. R21/Matrix-M in African Children Against Clinical Malaria (NCT04704830). https://clinicaltrials.gov/study/NCT04704830
- Gavi, the Vaccine Alliance. Gavi and UNICEF announce equitable pricing deal for malaria vaccine to protect 7 million more children by end of decade. November 24, 2025. https://www.gavi.org/news/media-room/gavi-and-unicef-announce-equitable-pricing-deal-malaria-vaccine-protect-7-million
- World Health Organization Regional Office for Africa. Nigeria Introduces the R21 Vaccine in a Pivotal Move for Malaria Control. December 5, 2024. https://www.afro.who.int/countries/nigeria/news/nigeria-introduces-r21-vaccine
Related coverage
Continue Exploring
Jump into the entities behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
